03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication....
15:21 , Mar 21, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; melanoma Mouse studies suggest inhibiting SMAD3 could help treat lung cancer and melanoma. In mouse models of lung cancer and melanoma, systemic knockout of SMAD3 decreased tumor growth and metastasis to the...
23:48 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor associated fibroblast levels of integrin α 5 β 1 , phosphorylated FAK , phosphorylated SMAD2 and phosphorylated SMAD3 could help predict outcomes in pancreatic ductal adenocarcinoma (PDAC) and renal cell carcinoma...
07:00 , Apr 3, 2014 |  BC Innovations  |  Targets & Mechanisms

Narrowing down graft stenosis

One of the dominant problems after coronary artery bypass graft surgery is hyperplastic growth inside the transplanted blood vessel that can lead to stenosis. Now, a team at the NIH 's National Heart, Lung, and...
07:00 , Jun 3, 2013 |  BioCentury  |  Product Development

The DMD landscape

Three companies are vying to gain the first approved drug for Duchenne muscular dystrophy in a race that has seen one company's stock soar 309% over the past year and the other two companies file...
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver fibrosis Mothers against decapentaplegic homolog 3 (MADH3; SMAD3); transforming growth factor receptor-b1 (TGFB1); vitamin D receptor (VDR) In vitro...
07:00 , Aug 6, 2012 |  BioCentury  |  Emerging Company Profile

Milo: Dismissing dystrophin

Milo Biotechnology LLC is developing a gene therapy to treat muscular dystrophy that up-regulates follistatin, a protein already present in the body, which could avoid immune reactions that have scuttled previous gene therapies. The company's...
08:00 , Feb 13, 2012 |  BioCentury  |  Emerging Company Profile

Halo: Treating DMD symptoms

Most companies developing therapeutics for Duchenne muscular dystrophy are targeting the genetic defects that cause the disease. Halo Therapeutics LLC , a company funded by two patient groups, thinks there is still room for treatments...
07:00 , Aug 11, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Obesity; diabetes Mothers against decapentaplegic homolog 3 (MADH3; SMAD3); transforming growth factor-b1 (TGFB1) Mouse studies suggest inhibiting TFGB1-SMAD3 signaling could treat obesity and...
07:00 , Jul 10, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Various Cancer; inflammatory disease Anaplastic lymphoma kinase 5 (ALK5; TGFBR1); membrane type 1 matrix metalloproteinase (MT1-MMP; MMP14); small mothers against decapentaplegic...